Literature DB >> 21199707

Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice.

Christopher Palma1, Michael G Overstreet, Jean-Marc Guedon, Egbert Hoiczyk, Cameron Ward, Kasey A Karen, Fidel Zavala, Gary Ketner.   

Abstract

Adenovirus particles can be engineered to display exogenous peptides on their surfaces by modification of viral capsid proteins, and particles that display pathogen-derived peptides can induce protective immunity. We constructed viable recombinant adenoviruses that display B-cell epitopes from the Plasmodium falciparum circumsporozoite protein (PfCSP) in the major adenovirus capsid protein, hexon. Recombinants induced high-titer antibodies against CSP when injected intraperitoneally into mice. Serum obtained from immunized mice recognized both recombinant PfCSP protein and P. falciparum sporozoites, and neutralized P. falciparum sporozoites in vitro. Replicating adenovirus vaccines have provided economical protection against adenovirus disease for over three decades. The recombinants described here may provide a path to an affordable malaria vaccine in the developing world.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21199707      PMCID: PMC3061321          DOI: 10.1016/j.vaccine.2010.12.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

1.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria.

Authors:  E G Rodrigues; F Zavala; D Eichinger; J M Wilson; M Tsuji
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

3.  A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.

Authors:  Nina Malkevitch; L Jean Patterson; Kristine Aldrich; Ersell Richardson; W Gregory Alvord; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

4.  Complementation of adenovirus E4 mutants by transient expression of E4 cDNA and deletion plasmids.

Authors:  G Ketner; E Bridge; A Virtanen; C Hemström; U Pettersson
Journal:  Nucleic Acids Res       Date:  1989-04-25       Impact factor: 16.971

5.  Maturation of the head of bacteriophage T4. IV. The proteins of the core of the tubular polyheads and in vitro cleavage of the head proteins.

Authors:  U K Laemmli; S F Quittner
Journal:  Virology       Date:  1974-12       Impact factor: 3.616

6.  Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.

Authors:  Bo Peng; Liqun Rejean Wang; Victor Raúl Gómez-Román; Alberta Davis-Warren; David C Montefiori; V S Kalyanaraman; David Venzon; Jun Zhao; Elaine Kan; Thomas J Rowell; Krishna K Murthy; Indresh Srivastava; Susan W Barnett; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.

Authors:  Stephen L Hoffman; Lucy M L Goh; Thomas C Luke; Imogene Schneider; Thong P Le; Denise L Doolan; John Sacci; Patricia de la Vega; Megan Dowler; Chris Paul; Daniel M Gordon; Jose A Stoute; L W Preston Church; Martha Sedegah; D Gray Heppner; W Ripley Ballou; Thomas L Richie
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

8.  Efficient induction of protective anti-malaria immunity by recombinant adenovirus.

Authors:  E G Rodrigues; F Zavala; R S Nussenzweig; J M Wilson; M Tsuji
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

9.  Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Ling Chen; Tong-Ming Fu; Robert K Evans; Michael J Caulfield; Mary-Ellen Davies; Aimin Tang; Minchun Chen; Lingyi Huang; Virginia Harris; Daniel C Freed; Keith A Wilson; Sheri Dubey; De-Min Zhu; Denise Nawrocki; Henryk Mach; Robert Troutman; Lynne Isopi; Donna Williams; William Hurni; Zheng Xu; Jeffrey G Smith; Su Wang; Xu Liu; Liming Guan; Romnie Long; Wendy Trigona; Gwendolyn J Heidecker; Helen C Perry; Natasha Persaud; Timothy J Toner; Qin Su; Xiaoping Liang; Rima Youil; Michael Chastain; Andrew J Bett; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Simple and highly efficient BAC recombineering using galK selection.

Authors:  Søren Warming; Nina Costantino; Donald L Court; Nancy A Jenkins; Neal G Copeland
Journal:  Nucleic Acids Res       Date:  2005-02-24       Impact factor: 16.971

View more
  16 in total

1.  A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys.

Authors:  Kasey A Karen; Cailin Deal; Robert J Adams; Carolyn Nielsen; Cameron Ward; Diego A Espinosa; Jane Xie; Fidel Zavala; Gary Ketner
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.

Authors:  Takayuki Shiratsuchi; Urvashi Rai; Izumi Kaneko; Min Zhang; Shiroh Iwanaga; Masao Yuda; Moriya Tsuji
Journal:  Vaccine       Date:  2017-10-28       Impact factor: 3.641

3.  Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.

Authors:  Bishnu P De; Odelya E Pagovich; Martin J Hicks; Jonathan B Rosenberg; Amira Y Moreno; Kim D Janda; George F Koob; Stefan Worgall; Stephen M Kaminsky; Dolan Sondhi; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2012-12-21       Impact factor: 5.695

4.  Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.

Authors:  Jonathan B Rosenberg; Bishnu P De; Martin J Hicks; Kim D Janda; Stephen M Kaminsky; Stefan Worgall; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2013-06       Impact factor: 5.695

5.  Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy.

Authors:  Diego A Espinosa; Anjali Yadava; Evelina Angov; Paul L Maurizio; Christian F Ockenhouse; Fidel Zavala
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

Review 6.  Prospects for oral replicating adenovirus-vectored vaccines.

Authors:  Cailin Deal; Andrew Pekosz; Gary Ketner
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

7.  Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein.

Authors:  Mitsuhiro Iyori; Hiroki Nakaya; Katsuya Inagaki; Sathit Pichyangkul; Daisuke S Yamamoto; Masanori Kawasaki; Kyungtak Kwak; Masami Mizukoshi; Yoshihiro Goto; Hiroyuki Matsuoka; Makoto Matsumoto; Shigeto Yoshida
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

8.  Using multivalent adenoviral vectors for HIV vaccination.

Authors:  Linlin Gu; Zan C Li; Alexandre Krendelchtchikov; Valentina Krendelchtchikova; Hongju Wu; Qiana L Matthews
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

9.  Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.

Authors:  Wai-Hong Wu; Tanwee Alkutkar; Balasubramanyan Karanam; Richard B S Roden; Gary Ketner; Okechukwu A Ibeanu
Journal:  Virol J       Date:  2015-09-11       Impact factor: 4.099

10.  A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.

Authors:  Jairo Andres Fonseca; Monica Cabrera-Mora; Elena A Kashentseva; John Paul Villegas; Alejandra Fernandez; Amelia Van Pelt; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.